Clinical Trials Logo

Filter by:
NCT ID: NCT03377595 Withdrawn - Pain, Postoperative Clinical Trials

Post C-Section Pain Control Using EXPAREL

Start date: July 2, 2019
Phase: Phase 4
Study type: Interventional

Evaluating the safety and efficacy of EXPAREL (Liposomal Bupivacaine ) for pain control in patients undergoing scheduled cesarean section by giving it either as infiltration in Transversus Abdominis Plane after finishing the procedure or through wound infiltration into the fascia prior to closure of skin

NCT ID: NCT03377426 Withdrawn - Clinical trials for Complicated Urinary Tract Infections

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Start date: October 19, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections

NCT ID: NCT03376984 Withdrawn - Clinical trials for Dental Pulp Necrosis

Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy

NDGX
Start date: June 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to to compare root canal therapy success between two root canal filler materials: 1) gutta percha (GP), 2) gutta percha modified with nanodiamonds and amoxicillin (NDGX). Gutta percha is the current standard root canal filler material used during non-surgical root canal therapy (RCT). Gutta percha modified with nanodiamonds and amoxicillin is an investigational root canal filler material, not yet FDA approved for use as described in this study. The safety and usefulness of NDGX is being tested in this study in comparison to the current standard of care, gutta percha (GP).

NCT ID: NCT03376854 Withdrawn - Sars-CoV2 Clinical Trials

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

CHILL-pilot
Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of ~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication of TH, often requiring paralysis with neuromuscular blocking agents (NMBA) to control. Since the recently completed NHLBI PETAL ROSE trial showed that NMBA had no effect (good or bad) in patients with moderate to severe ARDS, the investigators sought to evaluate whether TH combined with NMBA is beneficial in patients with ARDS. The investigators are scheduled to begin enrolling in a Department of Defense-funded Phase IIb multicenter RCT of TH (core temperature 34-35°C) + NMBA for 48h vs. usual temperature management in patients with ARDS with time on ventilator as the primary outcome. Since COVID-19 is now the most common cause of ARDS, we are conducting a pilot study to examine the safety and feasibility of including patients with COVID-19-associated ARDS in our upcoming trial. In this pilot, we will randomize 20 patients with COVID-19 and ARDS to either TH+NMBA for 48h or usual temperature management. The primary outcome is achieving and maintaining the target temperature. Secondary outcomes include safety, physiologic measures, mortality, hospital and ICU length of stay, and serum biomarkers collected on days 0, 1, 2, 3, 4, and 7.

NCT ID: NCT03376399 Withdrawn - Weight Loss Clinical Trials

Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms

Start date: October 25, 2017
Phase:
Study type: Observational

The purpose of this registry is to evaluate if sleeve gastrectomy surgery will help with symptoms of delayed gastric emptying for patients suffering from diabetic gastroparesis.

NCT ID: NCT03376139 Withdrawn - Clinical trials for Alcohol Use Disorder

Zonisamide Outpatient Study

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine if, compared to placebo, zonisamide (400mg/day) is a safe and efficacious treatment for post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) in Veterans with PTSD and co-occurring AUD.

NCT ID: NCT03374670 Withdrawn - Clinical trials for Idiopathic Polypoidal Choroidal Vasculopathy

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Start date: November 2018
Phase: Phase 2
Study type: Interventional

To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy

NCT ID: NCT03374605 Withdrawn - Anxiety and Fear Clinical Trials

Modulating Context Generalization Through Transcranial Direct Current Stimulation

Start date: February 2018
Phase: N/A
Study type: Interventional

Behavioral adaptation is particularly relevant to anxiety and related disorders, where exposure-based therapies rely on such adaptation as part of behavior therapy.. However, while initial fear reactions generalize easily across contexts, subsequent adaption of behavior through learning is context-specific. The primary goal of this study is to investigate whether transcranial direct current stimulation (tDCS) can be used to acutely impact generalization of subsequent learning across contexts in an experimental paradigm. As part of this study, participants will complete a clinical interview and questionnaires, as well as a computer task asking them to make choices between stimuli on the screen and during which they may or may not receive tDCS.

NCT ID: NCT03373305 Withdrawn - Sezary Syndrome Clinical Trials

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Start date: March 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide when given together with brentuximab vedotin in treating patients with T-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphomas.

NCT ID: NCT03372148 Withdrawn - Clinical trials for Head and Neck Cancer

Role of Pharyngeal High Resolution Manometry and Impedance in Swallow Function of Head and Neck Cancer Patients

Start date: December 2023
Phase: N/A
Study type: Interventional

Examining if the use of serial pHRMi to identify biomechanical changes in the swallow function of HNC patients treated with radiotherapy.